TY - JOUR
T1 - Emergence of the silicon human and network targeting drugs.
AU - Kolodkin, A.N.
AU - Boogerd, F.C.
AU - Plant, N.
AU - Bruggeman, F.J.
AU - Goncharuk, V.
AU - Lunshof, J.E.
AU - Moreno-Sanchez, R.
AU - Yilmaz, N.
AU - Bakker, B.M.
AU - Snoep, J.L.
AU - Balling, R.
AU - Westerhoff, H.V.
PY - 2012
Y1 - 2012
N2 - The development of disease may be characterized as a pathological shift of homeostasis; the main goal of contemporary drug treatment is, therefore, to return the pathological homeostasis back to the normal physiological range. From the view point of systems biology, homeostasis emerges from the interactions within the network of biomolecules (e.g. DNA, mRNA, proteins), and, hence, understanding how drugs impact upon the entire network should improve their efficacy at returning the network (body) to physiological homeostasis. Large, mechanism-based computer models, such as the anticipated human whole body models (silicon or virtual human), may help in the development of such network-targeting drugs. Using the philosophical concept of weak and strong emergence, we shall here take a more general look at the paradigm of network-targeting drugs, and propose our approaches to scale the strength of strong emergence. We apply these approaches to several biological examples and demonstrate their utility to reveal principles of bio-modeling. We discuss this in the perspective of building the silicon human. © 2011 Elsevier B.V. All rights reserved.
AB - The development of disease may be characterized as a pathological shift of homeostasis; the main goal of contemporary drug treatment is, therefore, to return the pathological homeostasis back to the normal physiological range. From the view point of systems biology, homeostasis emerges from the interactions within the network of biomolecules (e.g. DNA, mRNA, proteins), and, hence, understanding how drugs impact upon the entire network should improve their efficacy at returning the network (body) to physiological homeostasis. Large, mechanism-based computer models, such as the anticipated human whole body models (silicon or virtual human), may help in the development of such network-targeting drugs. Using the philosophical concept of weak and strong emergence, we shall here take a more general look at the paradigm of network-targeting drugs, and propose our approaches to scale the strength of strong emergence. We apply these approaches to several biological examples and demonstrate their utility to reveal principles of bio-modeling. We discuss this in the perspective of building the silicon human. © 2011 Elsevier B.V. All rights reserved.
UR - https://www.scopus.com/pages/publications/84861189361
UR - https://www.scopus.com/inward/citedby.url?scp=84861189361&partnerID=8YFLogxK
U2 - 10.1016/j.ejps.2011.06.006
DO - 10.1016/j.ejps.2011.06.006
M3 - Article
SN - 0928-0987
VL - 46
SP - 190
EP - 197
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
ER -